- Home
- SRBK vs ANVS Comparison
SRBK vs ANVS Comparison
Compare SRBK & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$2.47
Company Overview
Basic Information| Metric | SRBK | ANVS |
|---|---|---|
| Founded | 1887 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.7M | 111.3M |
| IPO Year | 2023 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SRBK | ANVS |
|---|---|---|
| Price | $17.16 | $2.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 29.5K | ★ 382.0K |
| Earning Date | 04-29-2026 | 03-16-2026 |
| Dividend Yield | ★ 1.20% | N/A |
| EPS Growth | ★ 138.36 | 39.39 |
| EPS | ★ 0.20 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $83.73 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.38 | $1.11 |
| 52 Week High | $18.04 | $5.50 |
Technical Indicators
Market Signals| Indicator | SRBK | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 54.95 | 45.85 |
| Support Level | $16.22 | $2.29 |
| Resistance Level | $17.14 | $2.63 |
| Average True Range (ATR) | 0.37 | 0.22 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 79.55 | 29.37 |
Price Performance
Historical Comparison SRBK
ANVS
About SRBK SR Bancorp Inc.
SR Bancorp Inc principal business is to acquire deposits from individuals and businesses in the communities surrounding offices and to use these deposits to fund loans.
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.